These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23161387)

  • 21. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.
    Gorello P; Cazzaniga G; Alberti F; Dell'Oro MG; Gottardi E; Specchia G; Roti G; Rosati R; Martelli MF; Diverio D; Lo Coco F; Biondi A; Saglio G; Mecucci C; Falini B
    Leukemia; 2006 Jun; 20(6):1103-8. PubMed ID: 16541144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
    Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
    Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant Enrichment with 3'-Modified Oligonucleotides (MEMO)-Quantitative PCR for Detection of NPM1 Mutations in Acute Myeloid Leukemia.
    Shin SY; Ki CS; Kim HJ; Kim JW; Kim SH; Lee ST
    J Clin Lab Anal; 2015 Sep; 29(5):361-5. PubMed ID: 25384962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of NPM1 gene mutations in acute myeloid leukemia].
    Dai D; Zhang SJ; Qiao C; Sun XM; Qian SX; Xu W; Xu YL; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):294-7. PubMed ID: 19379554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia.
    Reuter CW; Krauter J; Onono FO; Bunke T; Damm F; Thol F; Wagner K; Göhring G; Schlegelberger B; Heuser M; Ganser A; Morgan MA
    Ann Hematol; 2014 Jun; 93(6):977-82. PubMed ID: 24737308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.
    Kuo MC; Liang DC; Huang CF; Shih YS; Wu JH; Lin TL; Shih LY
    Leukemia; 2009 Aug; 23(8):1426-31. PubMed ID: 19282830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.
    Dunlap J; Beadling C; Warrick A; Neff T; Fleming WH; Loriaux M; Heinrich MC; Kovacsovics T; Kelemen K; Leeborg N; Gatter K; Braziel RM; Press R; Corless CL; Fan G
    Hum Pathol; 2012 Dec; 43(12):2167-76. PubMed ID: 22658276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
    Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
    Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1.
    Rozman M; Navarro JT; Arenillas L; Aventín A; Giménez T; Alonso E; Perea G; Camós M; Navarrete M; Tuset E; Florensa L; Millá F; Nomdedéu J; de la Banda E; Díaz-Beyá M; Pratcorona M; Garrido A; Navarro B; Brunet S; Sierra J; Esteve J;
    Ann Hematol; 2014 Oct; 93(10):1695-703. PubMed ID: 24824767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of rare NPM1 mutation subtypes by digital PCR.
    Bacher U; Dicker F; Haferlach C; Alpermann T; Rose D; Kern W; Haferlach T; Schnittger S
    Br J Haematol; 2014 Dec; 167(5):710-4. PubMed ID: 25039748
    [No Abstract]   [Full Text] [Related]  

  • 34. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia.
    Zhu YM; Foroni L; McQuaker IG; Papaioannou M; Haynes A; Russell HH
    Br J Cancer; 1999 Mar; 79(7-8):1151-7. PubMed ID: 10098750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype.
    Zhang Y; Zhang M; Yang L; Xiao Z
    Leuk Res; 2007 Jan; 31(1):109-11. PubMed ID: 16678898
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia.
    Ottone T; Ammatuna E; Lavorgna S; Noguera NI; Buccisano F; Venditti A; Giannì L; Postorino M; Federici G; Amadori S; Lo-Coco F
    J Mol Diagn; 2008 May; 10(3):212-6. PubMed ID: 18403613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases.
    Weisser M; Haferlach C; Haferlach T; Schnittger S
    Cancer Genet Cytogenet; 2007 Aug; 177(1):64-9. PubMed ID: 17693194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
    Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
    Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.
    Lu Y; Chen W; Chen W; Stein A; Weiss LM; Huang Q
    Am J Hematol; 2010 Jun; 85(6):426-30. PubMed ID: 20513120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of methods for detection of NPM1 gene mutations in acute myeloid leukemia].
    Li ZP; Zhang X; Zhao XM; Li QG; Chen YM; Lu QY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):999-1004. PubMed ID: 21867632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.